| Property | Value |
|---|---|
| Category | Angiogenesis / Neurovascular Therapy |
| Target | Parkinson's Disease |
| Mechanism | VEGF-mediated angiogenesis, BBB repair, neuroprotection |
| Development Stage | Preclinical to Phase 1 |
VEGF (Vascular Endothelial Growth Factor) and angiogenesis-based therapies represent a promising disease-modifying approach for Parkinson's disease that targets the growing recognition of neurovascular dysfunction as a key contributor to dopaminergic neurodegeneration. While traditionally focused on Alzheimer's disease, emerging evidence supports VEGF therapy as a potential intervention for PD through its effects on cerebral blood flow, blood-brain barrier integrity, and direct neuroprotective signaling on dopaminergic neurons.
The rationale for VEGF therapy in Parkinson's disease stems from the recognition that dopaminergic neurons in the substantia nigra pars compacta are particularly vulnerable to hypoxic and ischemic damage, and that restoring adequate blood supply and neurovascular coupling may protect remaining neurons and support recovery.
The neurovascular unit is progressively compromised in Parkinson's disease through multiple interconnected mechanisms:
Substantia nigra pars compacta dopaminergic neurons have:
VEGF signaling offers multiple therapeutic benefits for PD:
Research specifically examining VEGF in PD contexts shows dysregulated VEGF expression in PD patients, with both deficiency and excess having context-dependent effects[4].
| Component | VEGF Effect | PD-Specific Benefit |
|---|---|---|
| Endothelial Cells | Promote survival, enhance tight junctions | Restore barrier integrity |
| Pericytes | Support pericyte recruitment and function | Address pericyte loss |
| Astrocytes | Stabilize end-foot coverage | Improve neurovascular coupling |
| Neurons | Direct trophic support via VEGFR-1 | Protect dopaminergic neurons |
Studies in 6-hydroxydopamine (6-OHDA)-lesioned rats demonstrate:
In 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) models:
In alpha-synuclein overexpression models:
| Model | VEGF Effect | Outcome Measure |
|---|---|---|
| 6-OHDA rat | +40% TH+ neuron survival | Rotational behavior |
| MPTP mouse | Reduced DA neuron loss | Pole test, ladder walk |
| α-syn model | Decreased aggregation | Rotarod, cylinder test |
| Agent | Mechanism | PD-Specific Considerations |
|---|---|---|
| Cilostazol | PDE3 inhibitor, promotes angiogenesis | May improve cerebral blood flow |
| Statins | Pleiotropic angiogenic effects | Need BBB-penetrating formulations |
| Dimethyl fumarate | Nrf2 activation, vascular protection | Being explored in PD trials |
| Compound | Phase | Target | Status |
|---|---|---|---|
| AAV-VEGF (Cerebral) | Phase 1 | AD/PD | Recruiting |
| Cilostazol + Standard of Care | Phase 2 | PD with MCI | Ongoing |
| BMP9 (CDX2) | Phase 1 | Neurovascular regeneration | Preclinical for PD |
While VEGF therapy for neurodegenerative diseases has primarily focused on Alzheimer's disease, the shared neurovascular dysfunction between AD and PD creates opportunities for cross-indication development. Lessons learned from AD trials regarding dosing, delivery, and safety monitoring inform PD-specific approaches.
Common Adverse Effects:
PD-Specific Risks:
Contraindications:
VEGF angiogenesis therapy represents a promising disease-modifying approach for Parkinson's disease that addresses the increasingly recognized neurovascular component of PD pathophysiology. While preclinical evidence in PD models is encouraging, clinical development remains early-stage compared to Alzheimer's disease applications. The dual benefit of promoting cerebral blood flow while providing direct neuroprotection through neuronal VEGF receptors makes this approach attractive for further investigation.
Key research priorities include:
Friebe A, et al. Matrix metalloproteinases and BBB breakdown in Parkinson's disease. J Neuroinflammation. 2021. ↩︎
Yang P, et al. Pericyte loss in Parkinson's disease. Brain Pathology. 2020. ↩︎
Chiu GS, et al. Blood-brain barrier dysfunction in Parkinson's disease: Challenges and opportunities. Translational Neurodegeneration. 2022. ↩︎
Kotzbrot R, et al. VEGF and endothelial dysfunction in Parkinson's disease. J Parkinson's Disease. 2023. ↩︎
Tam SJ, et al. Angiogenesis in the central nervous system. Nat Rev Neurosci. 2019. ↩︎
Yasuhara T, et al. VEGF-induced neural protection in a rodent model of Parkinson's disease. J Cereb Blood Flow Metab. 2010. ↩︎
Zhang Z, et al. VEGF ameliorates dopaminergic neurodegeneration in MPTP-induced Parkinson's disease model. Exp Neurol. 2017. ↩︎
Kurosaki R, et al. Angiogenic factors improve motor function in alpha-synucleinopathy models. J Neurol Sci. 2019. ↩︎